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Cardiac Necrosis and Ischemia 
biomarkers
Cardiac Necrosis biomarkers
Troponins I and T
 The biochemical « gold standard »
 Specific of AMI
 I : completely specific for heart
 T: released small amounts by skeletal muscles
 Increase with cardiac insufficiency, angina…
 Elevated levels can persist for weeks; 
retrospective diagnosis of infraction.
 CKD
 New highly sensitive: good or more false 
positive: is what really necessary?
Ischemia biomarkers
H-FABP (heart-type fatty acid binding protein)
Ischemia biomarkers
H-FABP (heart-type fatty acid binding protein)
 Early rise marker of ACS (30 min following 
the onset of an ischemic episode)
Marker for re-infarction
Combination with Tn improve the 
diagnostic sensitivity for MI/ACS
Not widely use in practice
Myocyte injury/Stress
o Natriuretic peptide
o          BNP, NT-proBNP, ANP
o Especially useful in ruling out heart failure as 
cause of dyspnea given its excellent negative 
predictive value.





 Elevated after AMI and associated with LV 
dysfunction and remodeling and clinical HF post-
AMI
 In acute and chronic HF elevation of it 
predicts disease severity and poor outcome 
 99.7% NPV
 May obviate the need of prolonged monitoring 
and serial blood sampling
 Has been said>to and an additive to BNP
 Best single predictor of mortality in patients with 
NYHA functional class II and III
Myocyte injury/Stress
GDF 15
 Only detectable in liver and placenta can 
induced in the heart by MI and pressure 
overload
 Strong predictor of mortality in some patients
 Similar prognostic as NT=proBNP
 Role to play in diagnosis and risk stratification in 
HF
 The exact pathophysiological mechanisms of 
GDF-15 in the cardiovascular system and in 
acute ST-elevation myocardial infarction 
(STEMI) are not well defined. 
 Not widely use in practice
Remodeling biomarker
Matrix metalloproteinase (MMP9) :
 The main cause of fibrous cap disruption 
in plaque rupture
 Associated with higher mortality rates in 
HF --> Prognosis in HF
Remodeling biomarker
Galectin 3
 Link between inflammation and fibrosis
 Early marker of potential myocyte 
dysfunction and it may be a marker of 
early remodeling
 Increased in HF
Diagnostic role (<NT-proBNP)
 Prognosis (>to NT-proBNP in short term)
Inflammatory response
Highly sensitive CRP 
o Plasma levels can increase rapidly in 
response to acute inflammation
o Risk factor or risk marker?
MPO
 Activated leukocytes
 Predicts cardiac risk independently of 
other markers of inflammation
 IL (1,2,18)
              → NOT specific
Clinical advantages and disadvantages 












Multiple biomarkers approach show a 
best choice….
 TnThs…
Metabolomic and proteomic
